In a new article published on Tuesday, Newsweek spoke with a psychologist and psychiatrist who described Antiseptic Therapy (AT) as a bizarre and “crazy” idea.

Dr. Jeffrey R. Miller, a psychotherapist at the New York City Psychiatric Institute, said that although AT may help people overcome their depression and anxiety, its primary purpose is to reduce the ability to feel empathy.

Miller said that while AT is “a powerful tool,” it “is not an effective treatment for depression or anxiety.”

Miller said AT was a “predictive therapy” designed to teach people how to treat their symptoms, and that it “has no real scientific basis” as a treatment for anxiety disorders.

Miller told Newsweek that “people who have anxiety have very good and stable functioning, they have normal functioning, and it is not because of the medication.

It is the drugs.”

Miller told the magazine that AT “can only really help with depression and a handful of other anxiety disorders,” and that he doesn’t believe “AT is a valid treatment for people who have panic attacks or anxiety disorders, or for anxiety and depression, because it is very, very complicated.”

Miller also told Newsweek he doesn of “a lot of skepticism” about AT, stating that he believes “that people are trying to make money by using AT, and so it is all about money.”

Miller, who is also a clinical psychologist and researcher, also explained that AT can lead to “psychological damage” because it “fails to predict and mitigate the negative symptoms of anxiety and/or depression.”

He also said that “most people don’t understand that anxiety and depressed moods are not the same,” and argued that “the difference between anxiety and a depressed mood is not in the amount of negative thoughts.

It’s in the level of anxiety.”

In a follow-up interview with Newsweek, Miller told us that “psychiatrists” have a “very strong bias” against AT because of its “controversial nature,” saying that “there are a lot of people in psychiatry who have an emotional bias against it.

We’re not going to do this.”

Miller has also spoken out against the “overhyped” and “diseased” nature of AT in the media, and has argued that the “real problem” with AT is that “it’s marketed to children.”

According to Miller, the “treatment” is not “an effective treatment” for anxiety disorder because “it does not accurately predict what symptoms and severity of anxiety or depression you’ll be suffering from.”

Miller says he is “confident that this is the real problem,” and he is willing to “admit to [attempting] a more nuanced diagnosis” of depression and other anxiety conditions.

Newsweek has reached out to the pharmaceutical company Eli Lilly and Company for comment.